The DOI matches its Crossref record; 130 of the 130 references it cites were found in a registry or an index.
The Concept of an Ideal Antibiotic: Implications for Drug Design
Open accessAbstract
The emergence and spread of antibiotic-resistant pathogens is a major public health issue, which requires global action of an intersectoral nature. Multidrug-resistant (MDR) pathogens—especially “ESKAPE” bacteria—can withstand lethal doses of antibiotics with various chemical structures and mechanisms of action. Pharmaceutical companies are increasingly turning away from participating in the development of new antibiotics, due to the regulatory environment and the financial risks. There is an urgent need for innovation in antibiotic research, as classical discovery platforms (e.g., mining soil Streptomycetes) are no longer viable options. In addition to discovery platforms, a concept of an ideal antibiotic should be postulated, to act as a blueprint for future drugs, and to aid researchers, pharmaceutical companies, and relevant stakeholders in selecting lead compounds. Based on 150 references, the aim of this review is to summarize current advances regarding the challenges of antibiotic drug discovery and the specific attributes of an ideal antibacterial drug (a prodrug or generally reactive compound with no specific target, broad-spectrum antibacterial activity, adequate penetration through the Gram-negative cell wall, activity in biofilms and in hard-to-treat infections, accumulation in macrophages, availability for oral administration, and for use in sensitive patient groups).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Lipinski, C. A., Lombardo, F., Dominy, B. W., & Feeney, P. J. (2001) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(00)00129-0 · Cited by 18,139
Magiorakos, A.-P., Srinivasan, A., Carey, R. B., Carmeli, Y., Falagas, M. E., Giske, C. G., Harbarth, S., Hindler, J. F., Kahlmeter, G., Olsson-Liljequist, B., et al. (2012) · Clinical Microbiology and Infection · doi:10.1111/j.1469-0691.2011.03570.x · Cited by 14,449
Bad Bugs, No Drugs: No ESKAPE! An Update from the Infectious Diseases Society of America
Boucher, H. W., Talbot, G. H., Bradley, J. S., Edwards, J. E., Gilbert, D., Rice, L. B., Scheld, M., Spellberg, B., & Bartlett, J. (2009) · Clinical Infectious Diseases · doi:10.1086/595011 · Cited by 4,958
Antibiotic resistance-the need for global solutions
Laxminarayan, R., Duse, A., Wattal, C., Zaidi, A. K. M., Wertheim, H. F. L., Sumpradit, N., Vlieghe, E., Hara, G. L., Gould, I. M., Goossens, H., et al. (2013) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(13)70318-9 · Cited by 4,439
Drug-like properties and the causes of poor solubility and poor permeability
Lipinski, C. A. (2000) · Journal of Pharmacological and Toxicological Methods · doi:10.1016/s1056-8719(00)00107-6 · Cited by 3,734
Defensins: antimicrobial peptides of innate immunity
Ganz, T. (2003) · Nature Reviews Immunology · doi:10.1038/nri1180 · Cited by 3,066
Mechanisms of Antibiotic Resistance
Munita, J. M., & Arias, C. A. (2016) · Microbiology Spectrum · doi:10.1128/microbiolspec.vmbf-0016-2015 · Cited by 2,782
Drugs for bad bugs: confronting the challenges of antibacterial discovery
Payne, D. J., Gwynn, M. N., Holmes, D. J., & Pompliano, D. L. (2007) · Nature Reviews Drug Discovery · doi:10.1038/nrd2201 · Cited by 2,512
Dethlefsen, L., & Relman, D. A. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1000087107 · Cited by 2,421
A Diarylquinoline Drug Active on the ATP Synthase of Mycobacterium tuberculosis
Andries, K., Verhasselt, P., Guillemont, J., Göhlmann, H. W. H., Neefs, J.-M., Winkler, H., Van Gestel, J., Timmerman, P., Zhu, M., Lee, E., et al. (2005) · Science · doi:10.1126/science.1106753 · Cited by 2,191 · cited 1×
“Species-selective platform • Screening against a specific bug, resulting in compounds that act selectively against that pathogen [56] • Requires a target that is innate and specific to microorganism • Lower probability of toxicity in the human host • New compounds will not affect commensals in the gut [57] Bedaquiline…”
BackgroundOuter membrane permeability and antibiotic resistance
Delcour, A. H. (2009) · Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics · doi:10.1016/j.bbapap.2008.11.005 · Cited by 1,762
Three Decades of β-Lactamase Inhibitors
Drawz, S. M., & Bonomo, R. A. (2010) · Clinical Microbiology Reviews · doi:10.1128/cmr.00037-09 · Cited by 1,709
VÉZINA, C., KUDELSKI, A., & SEHGAL, S. N. (1975) · The Journal of Antibiotics · doi:10.7164/antibiotics.28.721 · Cited by 1,687
Multidrug Resistance in Bacteria
Nikaido, H. (2009) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.78.082907.145923 · Cited by 1,682
Mechanisms of Antimicrobial Resistance in ESKAPE Pathogens
Santajit, S., & Indrawattana, N. (2016) · BioMed Research International · doi:10.1155/2016/2475067 · Cited by 1,641
Platforms for antibiotic discovery
Lewis, K. (2013) · Nature Reviews Drug Discovery · doi:10.1038/nrd3975 · Cited by 1,445
Stenotrophomonas maltophilia: an Emerging Global Opportunistic Pathogen
Brooke, J. S. (2012) · Clinical Microbiology Reviews · doi:10.1128/cmr.00019-11 · Cited by 1,434
inhA , a Gene Encoding a Target for Isoniazid and Ethionamide in Mycobacterium tuberculosis
Banerjee, A., Dubnau, E., Quemard, A., Balasubramanian, V., Um, K. S., Wilson, T., Collins, D., de Lisle, G., & Jacobs, W. R. (1994) · Science · doi:10.1126/science.8284673 · Cited by 1,389
Persistent bacterial infections and persister cells
Fisher, R. A., Gollan, B., & Helaine, S. (2017) · Nature Reviews Microbiology · doi:10.1038/nrmicro.2017.42 · Cited by 1,243
Kumar, P., Kizhakkedathu, J., & Straus, S. (2018) · Biomolecules · doi:10.3390/biom8010004 · Cited by 1,227
Pankey, G. A., & Sabath, L. D. (2004) · Clinical Infectious Diseases · doi:10.1086/381972 · Cited by 1,201
Caenorhabditis elegans: An Emerging Model in Biomedical and Environmental Toxicology
Leung, M. C. K., Williams, P. L., Benedetto, A., Au, C., Helmcke, K. J., Aschner, M., & Meyer, J. N. (2008) · Toxicological Sciences · doi:10.1093/toxsci/kfn121 · Cited by 1,027
Strategies for combating bacterial biofilm infections
Wu, H., Moser, C., Wang, H.-Z., Høiby, N., & Song, Z.-J. (2015) · International Journal of Oral Science · doi:10.1038/ijos.2014.65 · Cited by 925
Bacterial Extracellular Polysaccharides in Biofilm Formation and Function
Limoli, D. H., Jones, C. J., & Wozniak, D. J. (2015) · Microbiology Spectrum · doi:10.1128/microbiolspec.mb-0011-2014 · Cited by 924
Lomovskaya, O., Warren, M. S., Lee, A., Galazzo, J., Fronko, R., Lee, M., Blais, J., Cho, D., Chamberland, S., Renau, T., et al. (2001) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.45.1.105-116.2001 · Cited by 903
Adaptive and Mutational Resistance: Role of Porins and Efflux Pumps in Drug Resistance
Fernández, L., & Hancock, R. E. W. (2012) · Clinical Microbiology Reviews · doi:10.1128/cmr.00043-12 · Cited by 892
What is antimicrobial stewardship?
Dyar, O. J., Huttner, B., Schouten, J., & Pulcini, C. (2017) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2017.08.026 · Cited by 870
The importance of efflux pumps in bacterial antibiotic resistance
Webber, M. A. (2003) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkg050 · Cited by 853
Cytochrome P450 Structure, Function and Clinical Significance: A Review
Manikandan, P., & Nagini, S. (2018) · Current Drug Targets · doi:10.2174/1389450118666170125144557 · Cited by 842
The biology and future prospects of antivirulence therapies
Cegelski, L., Marshall, G. R., Eldridge, G. R., & Hultgren, S. J. (2008) · Nature Reviews Microbiology · doi:10.1038/nrmicro1818 · Cited by 788
Bacteriophage Endolysins as Novel Antimicrobials
Schmelcher, M., Donovan, D. M., & Loessner, M. J. (2012) · Future Microbiology · doi:10.2217/fmb.12.97 · Cited by 785
Treatment with Monoclonal Antibodies against Clostridium difficile Toxins
Lowy, I., Molrine, D. C., Leav, B. A., Blair, B. M., Baxter, R., Gerding, D. N., Nichol, G., Thomas, W. D., Leney, M., Sloan, S., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0907635 · Cited by 746
Use of Ichip for High-Throughput In Situ Cultivation of “Uncultivable” Microbial Species
Nichols, D., Cahoon, N., Trakhtenberg, E. M., Pham, L., Mehta, A., Belanger, A., Kanigan, T., Lewis, K., & Epstein, S. S. (2010) · Applied and Environmental Microbiology · doi:10.1128/aem.01754-09 · Cited by 732
Bacterial Persister Cell Formation and Dormancy
Wood, T. K., Knabel, S. J., & Kwan, B. W. (2013) · Applied and Environmental Microbiology · doi:10.1128/aem.02636-13 · Cited by 703
Physicochemical Properties of Antibacterial Compounds: Implications for Drug Discovery
O’Shea, R., & Moser, H. E. (2008) · Journal of Medicinal Chemistry · doi:10.1021/jm700967e · Cited by 689
EUCAST expert rules in antimicrobial susceptibility testing
Leclercq, R., Cantón, R., Brown, D. F. J., Giske, C. G., Heisig, P., MacGowan, A. P., Mouton, J. W., Nordmann, P., Rodloff, A. C., Rossolini, G. M., et al. (2013) · Clinical Microbiology and Infection · doi:10.1111/j.1469-0691.2011.03703.x · Cited by 683
Metronidazole Is Still the Drug of Choice for Treatment of Anaerobic Infections
Löfmark, S., Edlund, C., & Nord, C. E. (2010) · Clinical Infectious Diseases · doi:10.1086/647939 · Cited by 656
Ein Beitrag zur Chemotherapie der bakteriellen Infektionen
Domagk, G. (1935) · DMW - Deutsche Medizinische Wochenschrift · doi:10.1055/s-0028-1129486 · Cited by 619
The Role of Reactive Oxygen Species in Antibiotic-Mediated Killing of Bacteria
Van Acker, H., & Coenye, T. (2017) · Trends in Microbiology · doi:10.1016/j.tim.2016.12.008 · Cited by 619
Takagi, T., Ramachandran, C., Bermejo, M., Yamashita, S., Yu, L. X., & Amidon, G. L. (2006) · Molecular Pharmaceutics · doi:10.1021/mp0600182 · Cited by 606
Antibiotic Adjuvants: Rescuing Antibiotics from Resistance
Wright, G. D. (2016) · Trends in Microbiology · doi:10.1016/j.tim.2016.06.009 · Cited by 604
Novel classes of antibiotics or more of the same?
Coates, A. R., Halls, G., & Hu, Y. (2011) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2011.01250.x · Cited by 598
The Discovery of Penicillin—New Insights After More Than 75 Years of Clinical Use
Gaynes, R. (2017) · Emerging Infectious Diseases · doi:10.3201/eid2305.161556 · Cited by 597
Cell Death from Antibiotics Without the Involvement of Reactive Oxygen Species
Liu, Y., & Imlay, J. A. (2013) · Science · doi:10.1126/science.1232751 · Cited by 593
Permeability Barrier of Gram-Negative Cell Envelopes and Approaches To Bypass It
Zgurskaya, H. I., López, C. A., & Gnanakaran, S. (2015) · ACS Infectious Diseases · doi:10.1021/acsinfecdis.5b00097 · Cited by 580
Daptomycin: a lipopeptide antibiotic for the treatment of serious Gram-positive infections
Steenbergen, J. N., Alder, J., Thorne, G. M., & Tally, F. P. (2005) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkh546 · Cited by 561
Killing by Bactericidal Antibiotics Does Not Depend on Reactive Oxygen Species
Keren, I., Wu, Y., Inocencio, J., Mulcahy, L. R., & Lewis, K. (2013) · Science · doi:10.1126/science.1232688 · Cited by 550
Almeida Da Silva, P. E., & Palomino, J. C. (2011) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkr173 · Cited by 532
Pyrazinamide Inhibits Trans-Translation in Mycobacterium tuberculosis
Shi, W., Zhang, X., Jiang, X., Yuan, H., Lee, J. S., Barry, C. E., Wang, H., Zhang, W., & Zhang, Y. (2011) · Science · doi:10.1126/science.1208813 · Cited by 514
Why is big Pharma getting out of antibacterial drug discovery?
Projan, S. J. (2003) · Current Opinion in Microbiology · doi:10.1016/j.mib.2003.08.003 · Cited by 503
Mycobacterium tuberculosis and the Macrophage: Maintaining a Balance
Pieters, J. (2008) · Cell Host & Microbe · doi:10.1016/j.chom.2008.05.006 · Cited by 503
The 10 × ‘20 Initiative: Pursuing a Global Commitment to Develop 10 New Antibacterial Drugs by 2020
(2010) · Clinical Infectious Diseases · doi:10.1086/652237 · Cited by 484
Prospects for plant-derived antibacterials
Lewis, K., & Ausubel, F. M. (2006) · Nature Biotechnology · doi:10.1038/nbt1206-1504 · Cited by 474
Systemic Antibiotic Therapy for Chronic Osteomyelitis in Adults
Spellberg, B., & Lipsky, B. A. (2012) · Clinical Infectious Diseases · doi:10.1093/cid/cir842 · Cited by 470
Strategies to Minimize Antibiotic Resistance
Lee, C.-R., Cho, I., Jeong, B., & Lee, S. (2013) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph10094274 · Cited by 446
Nation, R. L., & Li, J. (2009) · Current Opinion in Infectious Diseases · doi:10.1097/qco.0b013e328332e672 · Cited by 443
Nitazoxanide: A New Thiazolide Antiparasitic Agent
Fox, L. M., & Saravolatz, L. D. (2005) · Clinical Infectious Diseases · doi:10.1086/428839 · Cited by 443
The mutant selection window and antimicrobial resistance
Drlica, K. (2003) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkg269 · Cited by 437
Engineered Endolysin-Based “Artilysins” To Combat Multidrug-Resistant Gram-Negative Pathogens
Briers, Y., Walmagh, M., Van Puyenbroeck, V., Cornelissen, A., Cenens, W., Aertsen, A., Oliveira, H., Azeredo, J., Verween, G., Pirnay, J.-P., et al. (2014) · mBio · doi:10.1128/mbio.01379-14 · Cited by 421
Oxazolidinones: activity, mode of action, and mechanism of resistance
Bozdogan, B., & Appelbaum, P. C. (2004) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2003.11.003 · Cited by 403
Shannon, E., & Abu-Ghannam, N. (2016) · Marine Drugs · doi:10.3390/md14040081 · Cited by 385
Formation, physiology, ecology, evolution and clinical importance of bacterial persisters
Van den Bergh, B., Fauvart, M., & Michiels, J. (2017) · FEMS Microbiology Reviews · doi:10.1093/femsre/fux001 · Cited by 381
Antimicrobial Actions of Reactive Oxygen Species
Fang, F. C. (2011) · mBio · doi:10.1128/mbio.00141-11 · Cited by 371
Tackling Threats and Future Problems of Multidrug-Resistant Bacteria
Medina, E., & Pieper, D. H. (2016) · Current Topics in Microbiology and Immunology · doi:10.1007/82_2016_492 · Cited by 356
Mechanisms of Pyrazinamide Action and Resistance
Zhang, Y., Shi, W., Zhang, W., & Mitchison, D. (2014) · Microbiology Spectrum · doi:10.1128/microbiolspec.mgm2-0023-2013 · Cited by 332
Cystic fibrosis pathogenesis and the role of biofilms in persistent infection
Costerton, J. W. (2001) · Trends in Microbiology · doi:10.1016/s0966-842x(00)01918-1 · Cited by 331
A genomics-guided approach for discovering and expressing cryptic metabolic pathways
Zazopoulos, E., Huang, K., Staffa, A., Liu, W., Bachmann, B. O., Nonaka, K., Ahlert, J., Thorson, J. S., Shen, B., & Farnet, C. M. (2003) · Nature Biotechnology · doi:10.1038/nbt784 · Cited by 316
Mechanism of thioamide drug action against tuberculosis and leprosy
Wang, F., Langley, R., Gulten, G., Dover, L. G., Besra, G. S., Jacobs, W. R., & Sacchettini, J. C. (2007) · The Journal of Experimental Medicine · doi:10.1084/jem.20062100 · Cited by 303
Overview on mechanisms of isoniazid action and resistance in Mycobacterium tuberculosis
Unissa, A. N., Subbian, S., Hanna, L. E., & Selvakumar, N. (2016) · Infection, Genetics and Evolution · doi:10.1016/j.meegid.2016.09.004 · Cited by 300
Miller, S. I. (2016) · mBio · doi:10.1128/mbio.01541-16 · Cited by 260
Peng, Z., Jin, D., Kim, H. B., Stratton, C. W., Wu, B., Tang, Y.-W., & Sun, X. (2017) · Journal of Clinical Microbiology · doi:10.1128/jcm.02250-16 · Cited by 259
Origin and Proliferation of Multiple-Drug Resistance in Bacterial Pathogens
Chang, H.-H., Cohen, T., Grad, Y. H., Hanage, W. P., O'Brien, T. F., & Lipsitch, M. (2015) · Microbiology and Molecular Biology Reviews · doi:10.1128/mmbr.00039-14 · Cited by 243
Tuberculosis Treatment and Drug Regimens
Sotgiu, G., Centis, R., D'ambrosio, L., & Migliori, G. B. (2015) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a017822 · Cited by 241
The Soil as a Source of Microorganisms Antagonistic to Disease-Producing Bacteria
Waksman, S. A., & Woodruff, H. B. (1940) · Journal of Bacteriology · doi:10.1128/jb.40.4.581-600.1940 · Cited by 225
Haddad Kashani, H., Schmelcher, M., Sabzalipoor, H., Seyed Hosseini, E., & Moniri, R. (2018) · Clinical Microbiology Reviews · doi:10.1128/cmr.00071-17 · Cited by 225
Nahum, G. G., Uhl, K., & Kennedy, D. L. (2006) · Obstetrics & Gynecology · doi:10.1097/01.aog.0000216197.26783.b5 · Cited by 221
The selection and use of essential medicines.
Kazembe, P. N., Fannah, J. A., Hoppu, K., Zisovska, E., Pedersen, H., Hill, S., Ondari, C. O., Terlouw, D. J., Mattison, D. R., Zhi-ping, L., et al. (2004) · PubMed · Cited by 215
Nemeth, J., Oesch, G., & Kuster, S. P. (2015) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dku379 · Cited by 210
Intracellular pharmacodynamics of antibiotics
Carryn, S., Chanteux, H., Seral, C., Mingeot-Leclercq, M.-P., Van Bambeke, F., & Tulkens, P. M. (2003) · Infectious Disease Clinics of North America · doi:10.1016/s0891-5520(03)00066-7 · Cited by 201
What is an “ideal” antibiotic? Discovery challenges and path forward
Singh, S. B., Young, K., & Silver, L. L. (2017) · Biochemical Pharmacology · doi:10.1016/j.bcp.2017.01.003 · Cited by 201
L-form bacteria, cell walls and the origins of life
Errington, J. (2013) · Open Biology · doi:10.1098/rsob.120143 · Cited by 198
Tackling the threat of antimicrobial resistance: from policy to sustainable action
Shallcross, L. J., Howard, S. J., Fowler, T., & Davies, S. C. (2015) · Philosophical Transactions of the Royal Society B: Biological Sciences · doi:10.1098/rstb.2014.0082 · Cited by 196
Spengler, G., Kincses, A., Gajdács, M., & Amaral, L. (2017) · Molecules · doi:10.3390/molecules22030468 · Cited by 189
Self-citationAnti-biofilm agents: recent breakthrough against multi-drug resistant Staphylococcus aureus
Chung, P. Y., & Toh, Y. S. (2014) · Pathogens and Disease · doi:10.1111/2049-632x.12141 · Cited by 184
Busting the Myth of “Static vs Cidal”: A Systemic Literature Review
Wald-Dickler, N., Holtom, P., & Spellberg, B. (2018) · Clinical Infectious Diseases · doi:10.1093/cid/cix1127 · Cited by 174
Love, M., Bhandari, D., Dobson, R., & Billington, C. (2018) · Antibiotics · doi:10.3390/antibiotics7010017 · Cited by 173
Amaral, L., Martins, A., Spengler, G., & Molnar, J. (2014) · Frontiers in Pharmacology · doi:10.3389/fphar.2013.00168 · Cited by 170
Gajdács, M., Spengler, G., & Urbán, E. (2017) · Antibiotics · doi:10.3390/antibiotics6040025 · Cited by 169
Self-citationSpellberg, B. J. (2014) · Critical Care · doi:10.1186/cc13948 · Cited by 162
Pharmacokinetics and pharmacodynamics of ‘old’ polymyxins: what is new?
Bergen, P. J., Landersdorfer, C. B., Zhang, J., Zhao, M., Lee, H. J., Nation, R. L., & Li, J. (2012) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/j.diagmicrobio.2012.07.010 · Cited by 162
Engineering of obligate intracellular bacteria: progress, challenges and paradigms
McClure, E. E., Chávez, A. S. O., Shaw, D. K., Carlyon, J. A., Ganta, R. R., Noh, S. M., Wood, D. O., Bavoil, P. M., Brayton, K. A., Martinez, J. J., et al. (2017) · Nature Reviews Microbiology · doi:10.1038/nrmicro.2017.59 · Cited by 159
Microbial Efflux Pump Inhibition: Tactics and Strategies
Tegos, G. P., Haynes, M. K., Strouse, J. J., Khan, M. M. T., Bologa, C., Oprea, T. I., & Sklar, L. A. (2011) · Current Pharmaceutical Design · doi:10.2174/138161211795703726 · Cited by 158
Elemam, A., Rahimian, J., & Mandell, W. (2009) · Clinical Infectious Diseases · doi:10.1086/600042 · Cited by 156
Falagas, M. E., Rafailidis, P. I., Matthaiou, D. K., Virtzili, S., Nikita, D., & Michalopoulos, A. S. (2008) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2008.05.016 · Cited by 154
Bosnar, M., Kelnerić, Ž., Kos, V. M., Haber, V. E., & Parnham, M. J. (2005) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.49.6.2372-2377.2005 · Cited by 152
Oral Administration of Antibiotics: A Rational Alternative to the Parenteral Route
MacGregor, R. R., & Graziani, A. L. (1997) · Clinical Infectious Diseases · doi:10.1093/clinids/24.3.457 · Cited by 152
Novel Formulations for Antimicrobial Peptides
Carmona‐Ribeiro, A. M., & Carrasco, L. D. D. M. (2014) · International Journal of Molecular Sciences · doi:10.3390/ijms151018040 · Cited by 141
Antimicrobial Resistance Mechanisms and Potential Synthetic Treatments
Ali, J., Rafiq, Q. A., & Ratcliffe, E. (2018) · Future Science OA · doi:10.4155/fsoa-2017-0109 · Cited by 141
Discovery and preclinical development of new antibiotics
Hughes, D., & Karlén, A. (2014) · Upsala Journal of Medical Sciences · doi:10.3109/03009734.2014.896437 · Cited by 139
Helicobacter pylori in gastric carcinogenesis
Ahn, H. J., & Lee, D. (2015) · World Journal of Gastrointestinal Oncology · doi:10.4251/wjgo.v7.i12.455 · Cited by 139
Cellular pharmacodynamics and pharmacokinetics of antibiotics: current views and perspectives.
Françoise Van Bambeke, A., Barcia-Macay, M., Lemaire, S., & Tulkens, P. M. (2006) · PubMed · Cited by 138
Haque, S., Ahmad, F., Dar, S. A., Jawed, A., Mandal, R. K., Wahid, M., Lohani, M., Khan, S. A., Singh, V., & Akhter, N. (2018) · Microbial Pathogenesis · doi:10.1016/j.micpath.2018.05.046 · Cited by 136
Antibiotic Use in Children – A Cross-National Analysis of 6 Countries
Youngster, I., Avorn, J., Belleudi, V., Cantarutti, A., Díez‐Domingo, J., Kirchmayer, U., Park, B., Peiró, S., Sanfélix‐Gimeno, G., Schröder, H., et al. (2016) · The Journal of Pediatrics · doi:10.1016/j.jpeds.2016.11.027 · Cited by 132
New approaches to antimicrobial discovery
Lewis, K. (2016) · Biochemical Pharmacology · doi:10.1016/j.bcp.2016.11.002 · Cited by 126
L-form bacteria, chronic diseases and the origins of life
Errington, J., Mickiewicz, K. M., Kawai, Y., & Wu, L. J. (2016) · Philosophical Transactions of the Royal Society B Biological Sciences · doi:10.1098/rstb.2015.0494 · Cited by 124
Antibacterial Prodrugs to Overcome Bacterial Resistance
Jubeh, B., Breijyeh, Z., & Karaman, R. (2020) · Molecules · doi:10.3390/molecules25071543 · Cited by 109
The Role of Antibiotic Stewardship in Promoting Appropriate Antibiotic Use
Ha, D. R., Haste, N. M., & Gluckstein, D. P. (2017) · American Journal of Lifestyle Medicine · doi:10.1177/1559827617700824 · Cited by 102
An Unsupported Preference for Intravenous Antibiotics
Li, H. K., Agweyu, A., English, M., & Bejon, P. (2015) · PLoS Medicine · doi:10.1371/journal.pmed.1001825 · Cited by 92
Karaiskos, I., Galani, I., Souli, M., & Giamarellou, H. (2019) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2019.1563071 · Cited by 92
Polymyxin Delivery Systems: Recent Advances and Challenges
Dubashynskaya, N. V., & Skorik, Y. А. (2020) · Pharmaceuticals · doi:10.3390/ph13050083 · Cited by 89
Zhu, H., Swierstra, J., Wu, C., Girard, G., Choi, Y. H., van Wamel, W. J. B., Sandiford, S. K., & van Wezel, G. P. (2014) · Microbiology · doi:10.1099/mic.0.078295-0 · Cited by 88
Delafloxacin: design, development and potential place in therapy
Candel, F. J., & Peñuelas, M. (2017) · Drug Design Development and Therapy · doi:10.2147/dddt.s106071 · Cited by 73
ND4BB: addressing the antimicrobial resistance crisis
Rex, J. H. (2014) · Nature Reviews Microbiology · doi:10.1038/nrmicro3245 · Cited by 70
New approaches to antibiotic discovery
Kealey, C., Creaven, C. A., Murphy, C. D., & Brady, D. B. (2017) · Biotechnology Letters · doi:10.1007/s10529-017-2311-8 · Cited by 70
Jeverica, S., Kolenc, U., Mueller-Premru, M., & Papst, L. (2017) · Anaerobe · doi:10.1016/j.anaerobe.2017.04.007 · Cited by 67
Are natural products still the best source for antibacterial discovery? The bacterial entry factor
Silver, L. L. (2008) · Expert Opinion on Drug Discovery · doi:10.1517/17460441.3.5.487 · Cited by 67
Keeping it simple: lessons from the golden era of antibiotic discovery
Lyddiard, D., Jones, G. L., & Greatrex, B. W. (2016) · FEMS Microbiology Letters · doi:10.1093/femsle/fnw084 · Cited by 56
Tiz, D. B., Kikelj, D., & Zidar, N. (2018) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2018.1455660 · Cited by 54
Infectious Diseases Society of America (2008) · Clinical Infectious Diseases · doi:10.1086/591411 · Cited by 48
Intracellular Vesicles as Reproduction Elements in Cell Wall-Deficient L-Form Bacteria
Briers, Y., Staubli, T., Schmid, M. C., Wagner, M., Schuppler, M., & Loessner, M. J. (2012) · PLoS ONE · doi:10.1371/journal.pone.0038514 · Cited by 48
Drug Development and FDA Approval, 1938–2013
Darrow, J. J., & Kesselheim, A. S. (2014) · New England Journal of Medicine · doi:10.1056/nejmp1402114 · Cited by 47
Whole-Animal High-Throughput Screens: The C. elegans Model
O’Rourke, E. J., Conery, A. L., & Moy, T. I. (2009) · Methods in molecular biology · doi:10.1007/978-1-60327-545-3_5 · Cited by 46
Belfield, K., Bayston, R., Hajduk, N., Levell, G., Birchall, J. P., & Daniel, M. (2017) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkx192 · Cited by 46
Witek, K., Nasim, M. J., Bischoff, M., Gaupp, R., Arsenyan, P., Vasiljeva, J., Marć, M. A., Olejarz‐Maciej, A., Latacz, G., Kieć‐Kononowicz, K., et al. (2017) · Molecules · doi:10.3390/molecules22122174 · Cited by 41
Gajdács, M. (2020) · Antibiotics · doi:10.3390/antibiotics9040153 · Cited by 35
Self-citationButenko, T., Jeverica, S., Orel, R., & Homan, M. (2017) · Helicobacter · doi:10.1111/hel.12400 · Cited by 32
Adachi, T., Matsui, S., Watanabe, T., Okamoto, K., Okamoto, A., Kono, M., Yamada, M., Nagai, T., Komeda, Y., Minaga, K., et al. (2017) · Oncology · doi:10.1159/000481224 · Cited by 27
An Unmet Medical Need: Rapid Molecular Diagnostics Tests for Respiratory Tract Infections
Infectious Diseases Society of America (2011) · Clinical Infectious Diseases · doi:10.1093/cid/cir055 · Cited by 25
Chen, X., Zhu, Q., Liu, Y., Wang, R., HongYi, X., Chen, J., Cheng, Y., Zhang, H., Cao, L., & Chen, Y. (2020) · Infection and Drug Resistance · doi:10.2147/idr.s234186 · Cited by 23
Zhang, Y., Zheng, Y., Dong, F., Ma, H., Zhu, L., Shi, D., Li, X., Li, J., & Hu, J. (2020) · Infection and Drug Resistance · doi:10.2147/idr.s241263 · Cited by 18
Cited by
Muteeb, G., Rehman, M. T., Shahwan, M., & Aatif, M. (2023) · Pharmaceuticals · doi:10.3390/ph16111615 · Cited by 1,215
Algammal, A. M., Hetta, H. F., Elkelish, A., Alkhalifah, D. H. H., Hozzein, W. N., Batiha, G. E.-S., El Nahhas, N., & Mabrok, M. A. (2020) · Infection and Drug Resistance · doi:10.2147/idr.s272733 · Cited by 403
The Continuing Threat of Methicillin-Resistant Staphylococcus aureus
Gajdács, M. (2019) · Antibiotics · doi:10.3390/antibiotics8020052 · Cited by 318
Self-citationLeón-Buitimea, A., Garza-Cárdenas, C. R., Garza-Cervantes, J. A., Lerma-Escalera, J. A., & Morones-Ramírez, J. R. (2020) · Frontiers in Microbiology · doi:10.3389/fmicb.2020.01669 · Cited by 274
Aslam, A., Gajdács, M., Zin, C. S., Ab Rahman, N. S., Ahmed, S. I., Zafar, M. Z., & Jamshed, S. (2020) · Antibiotics · doi:10.3390/antibiotics9090597 · Cited by 142
Self-citation
Metadata
- Authors
- Gajdács, M.
- Venue
- Molecules
- Publisher
- MDPI AG
- Published
- 2019-03-03
- Volume
- 24
- Issue
- 5
- Pages
- 892
- ISSN
- 1420-3049 (ISSN-L)
- OpenAlex
- W2919650122
- Cited by
- 271
- References
- 130
- FWCI
- 16.04
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.